| XLS |
|
€ million |
Jan.–June |
Jan.–June |
|
Profit after tax |
260.1 |
381.5 |
|
Depreciation/amortization/impairment losses/write ups |
939.9 |
481.2 |
|
Changes in inventories |
–28.2 |
–36.6 |
|
Changes in trade accounts receivable |
–75.0 |
–230.0 |
|
Changes in trade accounts payable |
–111.8 |
28.3 |
|
Changes in provisions |
–1.4 |
51.9 |
|
Changes in other assets and liabilities |
–209.6 |
77.0 |
|
Neutralization of gain/loss on disposals of assets |
–205.5 |
–1.0 |
|
Other non-cash income and expenses |
8.6 |
–7.2 |
|
Net cash flows from operating activities |
577.1 |
744.9 |
|
|
|
|
|
Purchase of intangible assets |
–24.9 |
–31.0 |
|
Purchase of property, plant and equipment |
–160.8 |
–155.9 |
|
Acquisitions |
–10.1 |
– |
|
Investments in financial assets |
–4.3 |
–21.4 |
|
Disposal of non-current assets |
551.7 |
15.0 |
|
Purchase/sale of marketable securities |
–30.2 |
–0.5 |
|
Changes in financial assets covering pensions |
–3.1 |
–4.6 |
|
Changes in other financial assets |
–258.5 |
1,355.4 |
|
Net cash flows from investing activities |
59.8 |
1,157.0 |
|
|
|
|
|
Dividend payments |
–84.1 |
–71.6 |
|
Profit transfers to E. Merck KG and changes in reserves |
–166.6 |
–109.6 |
|
Changes in liabilities to E. Merck KG |
38.5 |
–58.1 |
|
Bonds issued |
– |
3,181.7 |
|
Changes in current and non-current financial liabilities |
–5.5 |
268.4 |
|
Net cash flows from financing activities |
–217.7 |
3,210.8 |
|
|
|
|
|
Changes in cash and cash equivalents |
419.3 |
5,112.8 |
|
Changes in cash and cash equivalents due to currency translation |
–9.0 |
17.6 |
|
Cash and cash equivalents as of January 1 (Group balance sheet) |
943.7 |
541.4 |
|
Plus cash and cash equivalents previously in assets held for sale |
1.2 |
– |
|
Cash and cash equivalents as of June 30 |
1,355.3 |
5,671.8 |
back
